



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/667,151	09/18/2003	Sheng-Ping Zhong	03-151US1	8726

27774 7590 08/28/2007
MAYER & WILLIAMS PC
251 NORTH AVENUE WEST
2ND FLOOR
WESTFIELD, NJ 07090

EXAMINER

RAE, CHARLESWORTH E

ART UNIT	PAPER NUMBER
----------	--------------

1614

MAIL DATE	DELIVERY MODE
-----------	---------------

08/28/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/667,151

Applicant(s)

ZHONG ET AL.

Examiner

Charlesworth Rae

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 February 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-39 is/are pending in the application.
- 4a) Of the above claim(s) 22-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-21, 38 and 39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

CLARIFICATION OF PREVIOUS OFFICE ACTION

The statutory response time period for responding to the Office action mailed 4/18/07 is being reset to start on the mailing date of this clarification Office action.

The following clarifications are intended to clarify inadvertent errors regarding the status of the claims that are currently pending in this application. The substantive rejections made in the Office action mailed on 4/18/07 are being maintained and are reiterated below.

It is noted that a corrected PTOL-326 form is enclosed to reflect the status of the pending claims. However, the examiner's initialed information disclosure (PTO/SB/08) forms and the Notice of References Cited (PTO-892) and accompanying copy of the cited non-patent literature reference previously made of record in the Office action mailed on 4/18/07 are not enclosed; the content of the PTO/SB/08 and PTO-892 are incorporated by reference.

Clarifications

Status of the Claims

Claims 1-39 are currently pending in this application and are the subject of the Office action.

Claims 22-37 are withdrawn from consideration for examination purposes for being directed towards non-elected subject-matter.

Claims 1-21, and 38-39 are presented for examination.

Restriction/Election requirements

The restriction requirement is maintained for the reasons made of record in the Office action mailed 12/21/06 (pages 2-5).

Applicant's argument, set forth in the response to the Office action mailed 12/21/06, that the species election requirement with respect to the species of chemical ablation agents is improper because the so-called "species" a), b) and e) overlaps in scope as do the species a) and c) and are therefore not mutually exclusive in view of MPEP 806.04(f) is deemed persuasive with respect to invention I. The species election requirement in connection with invention I is withdrawn regarding species a, b, c, and d, as these chemical ablation agent species are reasonably considered to be obvious variants of each other in view of applicant's argument.

Applicant's argument that the species election requirement with respect to the species of biodisintegrable viscosity adjusting agents overlap in scope and are not mutually exclusive is deemed to be persuasive. The species election requirement in connection with invention I is withdrawn as the claimed biodisintegrable viscosity adjusting agents are reasonably considered to be obvious variants of each other in view of applicant's argument.

Applicant's argument traversing the species election requirement with respect to the non-imaging contrast containing formulations and imaging contrast containing formulations encompassed by the claims is not deemed persuasive. To the extent that claim 14 depends from claim 1, the generic invention of claim 1 reasonably embraces non-imaging contrast agents.

For the reasons stated above, and of record, the restriction/election requirements are therefore made final.

Reiteration of the substantive rejections of record

Summary of Rejections

Claims 1-21 and 38-39 are rejected provisionally under the judicially created doctrine of nonstatutory obvious-type double patenting for reasons stated below.

Claims 1-21, and 38-39 are rejected under 103 (a) for reasons stated below.

Nonstatutory Obviousness-Type Double-Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-21, and 38-39 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 40 in view of claims 1-39 of U.S. Co-pending US Patent Application No. 11/124,828 (Pub. No. 2006/0251581 A1; referred herein as Appl. No. '828). Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are either anticipated by, or would have been obvious in view of the referenced claims.

Co-pending US Application No. 11/124,828/(Pub. No. 2006/0251581 A1; referred herein as McIntyre et al.) is directed towards a method for the treatment of uterine fibroids comprising providing an injectable or insertable formulation that comprises a uterine fibroid treatment agent in an amount effective to cause shrinkage of uterine fibrinoids, and injecting or inserting said formulation into the uterine fibroid.

In particular, claim 40 of the reference copending application is directed towards a fibroid injectable or insertable formulation that comprises a uterine fibroid treatment, selected from a non-steroidal anti-inflammatory drug, an oral contraceptive, a GnRH agonist, an antiprogesterone, and a selective progesterone receptor modulator, in an amount effective to cause shrinkage of uterine fibroids. To the extent that the reference claim 40 does not provide a clear or precise definition of the terms "uterine fibroid," or "fibroid injectable or insertable formulation," or "amount effective to cause shrinkage of uterine fibroids," to reasonable interpret the claim, it is reasonable to use the reference specification as a dictionary to determine

Art Unit: 1614

the meaning of the claim. McIntyre et al. define uterine fibroids, or uterine fibroid tumors, as non-cancerous smooth muscle tumors of the uterus (page 1, paragraph 0003, lines 1-3).

McIntyre et al. disclose that uterine fibroid treatment agents for inclusion in the formulation of the invention include chemical ablation agents, whose inclusion in the formulations in effective amounts results in necrosis (death) or shrinkage of nearby tissue upon injection or insertion of the formulation into the tissue (page 2, paragraph 0022). McIntyre et al. disclose that in some embodiments, the injectable or insertable formulations of the invention are solids, semi-solids or high-viscosity fluids, which result in good dosage retention in the tissue, and thereby improving delivery efficiency of the treatment agents and/or minimizing the adverse effects such as unintended, nonspecific tissue damage (page 1, paragraph 0015). McIntyre et al. disclose that "high viscous" or "high viscosity" and other such terms are used to describe fluids having viscosities greater than 1000 cps as measured by any number of techniques, including, for example, a Brookfield Kinematic Viscometer, model HBDV-II+CP with a CPE-40 cone spindle, set at 37 degrees C. temperature, and using a 0.5 rpm speed setting (page 2, column 1, lines 7-12). Reference claims 1-39 are generally directed to methods/system for treating uterine fibroids comprising a) an injectable or insertable formulation that comprises a uterine treatment agent in an amount effective to cause shrinkage of uterine fibroids and b) an apparatus for injecting or inserting said formulation into said fibroids. Further, reference methods/system claims 1-39 encompass chemical ablation agents (e.g. claims 1, and 14), biodegradable binders (e.g. claims 1, and 20), viscosity adjusting agents (e.g. claims 1, 26-28), alginate polymer (e.g. claims 1, and 34), and ionically crosslinked formulation (e.g. claims 1 and 33-34). Thus, the instant claimed

Art Unit: 1614

invention and the reference invention are reasonably considered to be obvious variants of each other.

Thus, claims 1-21, and 38-39 are deemed to be obvious variants of the limitations of reference claim 40 in view of reference claims 1-39.

This is a provisional obviousness-type double patenting rejection because the conflicting claims of the copending applications have not in fact been patented.

Claim rejections – 35 USC 103(a)

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-13, 19-21, and 38-39 are rejected as being unpatentable over Gentz et al. (US Patent 6,869,927 B1).

Gentz et al. teach liquid injectable formulations of keratinocyte growth factor-2 (KGF-2) and derivatives thereof (column 1, lines 19-24, and column 4, line 11-67), comprising KGF-2 polypeptides and sodium chloride as a tonicifier at a concentration of from about 0 to about 150 mM (NaCl) (column 4, line 34). Sodium chloride of about 150 mM is reasonably construed to serve as a chemical ablation agent in amount effective to cause tissue necrosis and to reasonably serve as a biodisintegrable viscosity adjusting agent in an amount effective to render the formulation highly viscous (see instant specification, page 3, paragraph 0019, line 1 to paragraph 0020, line 2; and page 5, paragraph 0026). Gentz et al. teach that the KGF-2 to be used for therapeutic administration may be sterile and that sterility is readily accomplished by filtration through sterile filtration membranes (column 14, lines 33-35). Sodium chloride is reasonably construed to be an osmotic-stress-generating agent in view of applicant's disclosure that "[I]n some embodiments, the ablation agents are osmotic-stress-generating agents, for example, a salt, such as sodium chloride (page 3, paragraph 0020, lines 1-2)." Gentz et al. teach that the formulations may employ "suitable pharmaceutical diluents," including but not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof (column 12, lines 29-34). "Suitable pharmaceutical diluentsand combination thereof" is reasonably construed to encompass an amount of water and ethanol suitable for the preparation of a sterile injectable formulation as claimed in the instant application (specification page 5, lines 1-2). . Gentz et al. teach that thickening agents are used to increase the viscosity of the formulation e.g. carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC),

Art Unit: 1614

hydroxypropylmethyl cellulose (HPMC), natrosol, and carbomers (column 2, lines 3-7).

Gentz et al. teach examples of etherified cellulose to include alkyl celluloses e.g.

methylcellulose, hydroxyethyl cellulose, hydroxyl propyl cellulose, hydroxyl propyl

methylcellulose, and the like (column 9, lines 5-9). Gentz et al. teach that when

thickening agents are added to the injectable formulations, salts and buffering agents

may be added or removed from the formulation for optimal stability (column 9, second

paragraph, lines 1-3). Gentz et al. teach that gelling agents may be added to the

injectable formulations, including vinyl polymers, polyoxyethylenepolyoxypropylene

copolymers, polysaccharides, proteins, poly(ethylene oxide), acrylamide polymers and

derivatives and salts thereof; useful polysaccharides include cellulose derivatives,

glycosaminoglycans, agar, pectin, alginate acid, dextran, starch, and chitosan (column

10, lines 19-51). Based on this teaching, ionically cross-linkable polymers such as

alginate polymer are reasonably within the capabilities of someone of skill in the art.

Gentz et al. teach that additional stabilizing agents may be added to the formulation,

including anionic and polyanionic species [heparin analogs] (column 11, line 65 to

column 12, line 27). Gentz et al teach that the formulations are prepared contacting the

KGF-2 polypeptide uniformly and intimately with liquid carriers or finely divided solid

carriers or both (column 13, lines 63-65). Gentz et al. also teach that the carrier may

also contain minor amounts of suitable additives such as substances that enhance

isotonicity and chemical stability e.g. phosphate, citrate, succinate, acetic acid, and

other organic acids or their salts; antioxidants such as ascorbic acid; low molecular

weight polypeptides e.g. polyarginine or tripeptides; proteins, such as serum albumin,

Art Unit: 1614

gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; ... (column 14, lines 9-25). Gentz et al. teach high molecular weight polymers of acrylic acid cross-linked with either allyl ethers of pentaerythritol (column 9, lines 1-5). Gentz et al. teach that the thickening agent should raise the viscosity to about 50 to about 10,000 centipoise (cps); the viscosity is measured using a rotating spindle viscometer (column 8, last paragraph, last paragraph). The term "about 10,000" is reasonable construed to overlap with the instant claimed limitation of "from 5,000 cps to 100,000 cps" and "from 10,000 cps to 50,000 cps." Gentz et al. disclosed formulations reasonably encompass injectable formulations comprising a plurality of ablation agents. For example, reference claim 72, is directed toward a composition comprising a polypeptide, hydroxymethylcellulose, sucrose, sodium citrate, sodium chloride, and EDTA. To the extent that reference claim 72 recites the term "comprising," it is reasonable to construe the reference claim as contemplating the addition of other ablation agents and additional viscosity adjusting agents besides sodium chloride, which reasonably satisfies the "plurality of viscosity adjusting agent" and "plurality of ablation agents" limitations.

Thus, based on the teaching of Gentz et al., someone of skill in the art would have been motivated, and deemed it obvious, at the time the instant claimed invention was made to create the instant invention with a reasonable expectation of success.

Rejection under 103

Claims 14-18 are rejected as being unpatentable over Gentz et al (US Patent 6,869,927 B1), in view of Flacke et al. (Novel MRI contrast agent for molecular imaging

Art Unit: 1614

of fibrin –implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285), in view of Glajch et al. (US Patent 5,147,631).

The above discussion of Gentz et al. is incorporated by reference. It is noted that Gentz et al. do not teach imaging contrast agent.

Flacke et al. teach a fibrin-specific MR contrast agent that could allow enhanced, sensitive detection and quantification of occult microthrombi within the intimal surface of atherosclerotic vessels in symptomatic patients and provide direct evidence to support acute therapeutic intervention (page 1280, last paragraph, line 1 to page 1281, line 6).

Glajch et al. teach ultrasound contrast agents comprising porous particles of an inorganic material having an average particle diameter of about 0.05 to 500 microns and containing entrapped gas or liquid; the inorganic material includes monomeric and polymeric forms of one or more of the following: borates, aluminas, carbonates, silicates, silicas, aluminosilicates, phosphates, and organic or inorganic cationic salts thereof (column 2, lines 11-27). This teaching is reasonably construed to satisfy the “wherein the plurality of solid particles is selected from calcium carbonate particles ...” instant claim limitation. For parenteral use, the particles are preferably about 0.2-10 microns in average diameter (column 2, lines 33-34). Glajch et al. teach that these contrast agents are useful for ultrasound imaging of a body organ system (column 2, lines 66-68).

Based on the teaching of Glajch et al. of ultrasound contrast agents useful for ultrasound imaging of a body organ system, someone of skill in the art would have been motivated to combine the teachings of Gentz et al., in view of Flacke et al., in view of Glajch et al. to reasonably assess the efficacy of the injectable formulation of Gentz. Thus, someone of skill in

Art Unit: 1614

the art would have deemed it obvious at the time the instant invention was made to create the instant invention with a reasonable expectation of success.

For the above reasons, someone of skill in the art would have deemed it obvious to create the instant invention with a reasonable expectation of success in view of

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charlesworth Rae whose telephone number is 571-272-6029.

The examiner can normally be reached between 9 a.m. to 5:30 p.m. Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached at 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 800-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

21 August 2007
CER

 8/24/07
ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER